Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 4/20 | 0.41 |
| ▸ | CCNC | P24863 | 1/20 | 0.41 |
| ▸ | CDK8 | P49336 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.37 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4580845 | 0.90 | MMP2 (0.46) | ADRA2AADRA2BADRA2CADRA1AMMP2 | |
| SCHEMBL4580442 | 0.86 | P4HTM (0.43) | MMP2CCNCCDK8KDM4EKMT2A | |
| SCHEMBL4581123 | 0.85 | TAS2R14 (0.43) | MMP2CCNCCDK8KDM4EGSK3A | |
| SCHEMBL4582757 | 0.85 | GSK3A (0.42) | MMP2CCNCCDK8KDM4EKMT2A | |
| SCHEMBL4580475 | 0.83 | AKR1C3 (0.48) | KMT2AGSK3AGSK3BMEN1LMNA | |
| SCHEMBL4581447 | 0.82 | CCNC (0.39) | MMP2CCNCCDK8KDM4EKMT2A | |
| SCHEMBL4580993 | 0.80 | KDM4E (0.41) | MMP2CCNCCDK8KDM4EKMT2A | |
| SCHEMBL4581101 | 0.80 | KDM4C (0.49) | ADRA2CKDM4EKMT2AKDM4CMEN1 | |
| SCHEMBL14368822 | 0.79 | AKR1C3 (0.40) | ADRA2AADRA2BADRA2CADRA1AMMP2 | |
| SCHEMBL5183236 | 0.76 | MPO (0.50) | MMP2KMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080032991-A1 | 2, 8-disubstituted Naphthyridine Derivatives | SERENEX, INC. | 2008-02-07 | — | — | US | claimed |
| US-7282506-B2 | 2,8-disubstituted naphthyridine derivatives | SERENEX, INC. (US) | 2007-10-16 | — | — | US | claimed |
| EP-1773834-A2 | 2, 8-DISUBSTITUTED NAPHTHYRIDINE DERIVATIVES | Serenex, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006017672-A2 | 2, 8-DISUBSTITUTED NAPHTHYRIDINE DERIVATIVES | SERENEX INC. (US) | 2006-02-16 | — | — | WO | claimed |
| US-20060030584-A1 | 2,8-Disubstituted naphthyridine derivatives | SERENEX, INC. | 2006-02-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030584-A1 | 2,8-Disubstituted naphthyridine derivatives | CCNA1, FOXM1, CCNA2 | ADRA2A 191/4885ADRA2B 578/4885ADRA2C 428/4885 |
| US-20080032991-A1 | 2, 8-disubstituted Naphthyridine Derivatives | CCNA1, FOXM1, CCNA2 | ADRA2A 191/4885ADRA2B 578/4885ADRA2C 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.